000180781 001__ 180781
000180781 005__ 20241228120953.0
000180781 0247_ $$2doi$$a10.1007/s00432-022-04204-w
000180781 0247_ $$2pmid$$apmid:35879433
000180781 0247_ $$2ISSN$$a0084-5353
000180781 0247_ $$2ISSN$$a0171-5216
000180781 0247_ $$2ISSN$$a0943-9382
000180781 0247_ $$2ISSN$$a1432-1335
000180781 0247_ $$2altmetric$$aaltmetric:133137592
000180781 037__ $$aDKFZ-2022-01546
000180781 041__ $$aEnglish
000180781 082__ $$a610
000180781 1001_ $$0P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDoege, Daniela$$b0$$eFirst author$$udkfz
000180781 245__ $$aClinical and sociodemographic determinants of disease-specific health-related quality of life in long-term breast cancer survivors.
000180781 260__ $$aHeidelberg$$bSpringer$$c2022
000180781 3367_ $$2DRIVER$$aarticle
000180781 3367_ $$2DataCite$$aOutput Types/Journal article
000180781 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1666789052_11982
000180781 3367_ $$2BibTeX$$aARTICLE
000180781 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180781 3367_ $$00$$2EndNote$$aJournal Article
000180781 500__ $$a#EA:C071#LA:C071# / 2022 Dec;148(12):3461-3473
000180781 520__ $$aIt is important to monitor disease-specific health-related quality of life (HRQoL) in breast cancer (BC) survivors to identify potential unmet supportive care needs. However, previous studies were characterized by small samples of mostly short-term survivors and were limited to certain age ranges, stages and/or treatments.We used data from 3045 long-term BC survivors (5-15 years post-diagnosis) recruited in a German multi-regional population-based study. We assessed disease-specific HRQoL with the EORTC QLQ-BR23, scoring from 0 to 100. Differences in functioning and symptoms according to age at survey, self-reported treatments, stage, and disease status (disease-free vs. active disease) were assessed with multiple regression. Active disease was defined as any self-report of recurrence, metastasis or second primary cancer after the index cancer.Older BC survivors reported a higher body image and a better future perspective, but lower sexual functioning. Survivors aged 30-49 years who had breast-conserving therapy or mastectomy with breast reconstruction reported a better body image compared to those who had mastectomy only. We also found differences in symptoms according to treatments in some age groups. Stage at diagnosis was not associated with HRQoL overall and in most age subgroups. Disease-free BC survivors aged 30-79 years reported a better future perspective and less systemic therapy side effects than those with active disease.Several treatment-associated symptoms and functioning detriments were found 5-15 years after diagnosis. The results emphasize the need of a comprehensive, individualized survivorship care, recognizing differential needs of long-term BC survivors according to age, treatment modalities, and disease status.
000180781 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000180781 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180781 650_7 $$2Other$$aAdverse effects
000180781 650_7 $$2Other$$aBody image
000180781 650_7 $$2Other$$aBreast cancer survivors
000180781 650_7 $$2Other$$aDisease-specific issues
000180781 650_7 $$2Other$$aHair loss
000180781 650_7 $$2Other$$aQuality of life
000180781 650_7 $$2Other$$aSexuality
000180781 7001_ $$0P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aThong, Melissa$$b1$$udkfz
000180781 7001_ $$0P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aKoch-Gallenkamp, Lena$$b2$$udkfz
000180781 7001_ $$aBertram, Heike$$b3
000180781 7001_ $$aEberle, Andrea$$b4
000180781 7001_ $$aHolleczek, Bernd$$b5
000180781 7001_ $$aNennecke, Alice$$b6
000180781 7001_ $$aPritzkuleit, Ron$$b7
000180781 7001_ $$aWaldmann, Annika$$b8
000180781 7001_ $$aZeissig, Sylke R$$b9
000180781 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b10$$udkfz
000180781 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b11$$eLast author$$udkfz
000180781 773__ $$0PERI:(DE-600)1459285-X$$a10.1007/s00432-022-04204-w$$n12$$p3461-3473$$tJournal of cancer research and clinical oncology$$v148$$x0171-5216$$y2022
000180781 8767_ $$8V52536$$92023-12-01$$d2024-12-27$$eHybrid-OA$$jZahlung erfolgt
000180781 909CO $$ooai:inrepo02.dkfz.de:180781$$pVDB$$popenCost$$pOpenAPC
000180781 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000180781 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000180781 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000180781 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000180781 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000180781 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000180781 9141_ $$y2022
000180781 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-31$$wger
000180781 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-31
000180781 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-31
000180781 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-31
000180781 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000180781 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000180781 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000180781 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-17
000180781 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-17
000180781 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000180781 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CANCER RES CLIN : 2021$$d2022-11-17
000180781 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-17
000180781 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-17
000180781 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-17
000180781 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000180781 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000180781 9202_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000180781 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000180781 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000180781 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x2
000180781 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000180781 9200_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000180781 980__ $$ajournal
000180781 980__ $$aVDB
000180781 980__ $$aI:(DE-He78)C071-20160331
000180781 980__ $$aI:(DE-He78)C070-20160331
000180781 980__ $$aI:(DE-He78)C120-20160331
000180781 980__ $$aI:(DE-He78)HD01-20160331
000180781 980__ $$aUNRESTRICTED
000180781 980__ $$aAPC